Shareholders file suit against KV Pharma

Problems continue to mount for KV Pharmaceuticals. Over the past two months, several groups of shareholders and former employees have filed suits against the company. The latest lawsuit was filed earlier this week in the District Court for the Eastern District of Missouri. The complaints allege that KV Pharmaceuticals misled shareholders about KV's compliance with federal regulations, as well as the company's performance, operations and outlook.

According to shareholders, KV continued to produce unsafe drug products in poorly managed facilities that did not meet the FDA's Good Manufacturing Practices. The complaint also alleges that not only did KV fail to recall unsafe drug products, but inefficiencies at the plants created a backlog that resulted in further loss of revenue and earnings.

Last year, federal regulators seized $24 million in drug products from KV's manufacturing facilities after the company ignored warnings to discontinue the manufacturing and distribution of unapproved products. Shareholders are also seeking damages for KV's failure to write-off that $24 million in discontinued products.

- check out the release for more

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.